• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

9.400 +0.670 (+7.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,397,686
Open 8.720
Bid (Size) 8.800 (1)
Ask (Size) 10.00 (3)
Prev. Close 8.730
Today's Range 8.590 - 9.420
52wk Range 3.300 - 11.40
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 02, 2025
 
Via Benzinga
Immatics Appoints Venkat Ramanan as Chief Financial Officer
October 01, 2025
From https://immatics.com/
Via GlobeNewswire

Performance

YTD
+26.7%
+26.7%
1 Month
+72.5%
+72.5%
3 Month
+69.8%
+69.8%
6 Month
+168.6%
+168.6%
1 Year
-9.2%
-9.2%

More News

Read More
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
August 19, 2025
Via Benzinga
Immatics Announces Second Quarter 2025 Financial Results and Business Update
August 13, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
May 31, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics Announces First Quarter 2025 Financial Results and Business Update
May 13, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
April 23, 2025
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Full Year 2024 Financial Results and Business Update
March 27, 2025
From https://immatics.com/
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 03, 2025
Via Benzinga
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
November 18, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
November 08, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Pricing of $150 Million Public Offering
October 10, 2024
From https://immatics.com/
Via GlobeNewswire
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
October 10, 2024
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 10, 2024
Via Benzinga
Immatics Announces Proposed $150 Million Public Offering
October 10, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
October 10, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
October 04, 2024
From https://immatics.com/
Via GlobeNewswire
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
October 01, 2024
Via Talk Markets
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
September 16, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
September 06, 2024
From https://immatics.com/
Via GlobeNewswire
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q2 2024
August 13, 2024
Via InvestorPlace
Immatics Announces Second Quarter 2024 Financial Results and Business Update
August 13, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Appoints Alise Reicin to Board of Directors
July 31, 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
July 18, 2024
From https://immatics.com/
Via GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Via Talk Markets

Frequently Asked Questions

Is Immatics N.V. - Ordinary Shares publicly traded?
Yes, Immatics N.V. - Ordinary Shares is publicly traded.
What exchange does Immatics N.V. - Ordinary Shares trade on?
Immatics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Immatics N.V. - Ordinary Shares?
The ticker symbol for Immatics N.V. - Ordinary Shares is IMTX on the Nasdaq Stock Market
What is the current price of Immatics N.V. - Ordinary Shares?
The current price of Immatics N.V. - Ordinary Shares is 9.400
When was Immatics N.V. - Ordinary Shares last traded?
The last trade of Immatics N.V. - Ordinary Shares was at 10/03/25 04:00 PM ET
Recent Quotes
View More
Symbol Price Change (%)
GOOG  246.45
+0.02 (0.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap